* Precipio Inc PRPO.OQ PRPO.O is expected to report
results on May 9 (estimated).
*
* Refinitiv's mean analyst estimate for Precipio Inc is for
a
loss of 13 cents per share.
* The one available analyst rating on the shares is "buy".
* The average consensus recommendation for the advanced
medical
equipment & technology peer group is also "Buy".
* Wall Street's median 12-month price target for Precipio
Inc is
$2.85, above its last closing price of $0.57.
This summary was machine generated May 6 at 02:05 GMT. All
figures in US dollars unless otherwise stated